{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:44:20Z","timestamp":1776930260714,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LGC\/004\/2018"],"award-info":[{"award-number":["NMRC\/LGC\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to evaluate influence of baseline imaging features on visual and anatomical outcomes in eyes with PCV treated with anti-VEGF monotherapy. In this prospective study we enrolled participants with treatment-na\u00efve PCV who followed a treat-and-extend protocol using intravitreal aflibercept (IVA) monotherapy. Baseline clinical features evaluatedincluded best corrected visual acuity (BCVA), traditional features such as lesion size,\u00a0fluid-related OCT parameters and novel parameters using automated software. This included quantitative and qualitative pigment epithelium detachment (PED) parameters [height, volume]; and choroidal parameters. [choroidal thickness (CT), choroidal volume (CV) and choroidal vascularity index (CVI). We evaluated the predictive value of each parameter on visual and anatomical outcome at month 12. We additionally evaluated initial treatment response after 3 monthly injections with respect to month 12 outcomes. Fifty-two eyes from 52 participants were included in the study. The BCVA increased from 61.1\u2009\u00b1\u200913.2 to 69.6\u2009\u00b1\u200913.2 early treatment diabetic retinopathy study (ETDRS) letters (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and CRT reduced from 455.7\u2009\u00b1\u2009182.4\u00a0\u00b5m to 272.7\u2009\u00b1\u200986.2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) from baseline to month 12. The proportion of eyes with PED decreased significant from 100% at baseline to 80% at month 12 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Reduction in the mean maximum height of PED (from 381.3\u2009\u00b1\u2009236.3\u00a0\u00b5m to 206.8\u00a0vs\u2009\u00b1\u2009146.4\u00a0\u00b5m) and PED volume (from 1322\u2009\u00b1\u2009853\u00a0nl to 686\u2009\u00b1\u2009593\u00a0nl) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) was also noted from baseline to month12. Baseline features associated with better month 12 BCVA included baseline BCVA (\u03b2\u2009=\u2009\u2009\u2212\u20090.98, 95%CI\u2009\u2212\u20093.38 to\u2009\u2212\u20091.61, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) and baseline CRT (\u03b2\u2009=\u2009\u2009\u2212\u20090.98, 95%CI\u2009\u2212\u20091.56 to\u2009\u2212\u20090.40, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) while the disease activity at month12 was significantly associated with lower baseline CRT (366.0\u2009\u00b1\u2009129.5 vs 612.0\u2009\u00b1\u2009188.0 , <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), lower baseline PED height (242.0\u2009\u00b1\u2009150.0 vs 542.0\u2009\u00b1\u2009298.0\u00a0\u00b5m, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), lower baseline PED volume (0.6\u2009\u00b1\u20090.3 mm<jats:sup>3<\/jats:sup> vs 2.2\u2009\u00b1\u20091.3 mm<jats:sup>3<\/jats:sup> vs, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), lower proportion with marked CVH (17.9% vs 46.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) and lower mean CVI (61.8\u2009\u00b1\u20091.4 vs 63.0\u2009\u00b1\u20091.4, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02). Additionally, a larger decrease in CRT (per 100\u00a0nm) and larger PED volume reduction (per 100\u00a0nl) at month 3 from baseline were associated with greater BCVA gain and inactive disease. PED-related volumetric parameters have an additional predictive value to traditional biomarkers of disease activity in eyes with PCV undergoing anti-VEGF monotherapy. With increasingly precise quantification, PEDs can be a crucial biomarker in addition to traditional parameters and may aid in retreatment decisions.\n<\/jats:p>","DOI":"10.1038\/s41598-022-06742-2","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T11:02:51Z","timestamp":1645527771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV"],"prefix":"10.1038","volume":"12","author":[{"given":"Chinmayi Himanshuroy","family":"Vyas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice Marie N.","family":"Jordan-Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Cheng Sim","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun Sebastian","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beau James","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin Yi Chong","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"6742_CR1","doi-asserted-by":"publisher","unstructured":"Busbee, B. G., Ho, A. C. & Brown, D. M. et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046\u201356. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.014","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"6742_CR2","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff, C. C. et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122, 2514\u20132522. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.009 (2015).","journal-title":"Ophthalmology"},{"key":"6742_CR3","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","volume":"122","author":"G Ying","year":"2015","unstructured":"Ying, G. et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology 122, 2523-2531.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.015 (2015).","journal-title":"Ophthalmology"},{"key":"6742_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","volume":"117","author":"LA Yannuzzi","year":"1999","unstructured":"Yannuzzi, L. A. et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch. Ophthalmol. 117, 1503\u20131510. https:\/\/doi.org\/10.1001\/archopht.117.11.1503 (1999).","journal-title":"Arch. Ophthalmol."},{"key":"6742_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s004170000180","volume":"238","author":"BA Lafaut","year":"2000","unstructured":"Lafaut, B. A. et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch. Clin. Exp. Ophthalmol. 238, 752\u2013759. https:\/\/doi.org\/10.1007\/s004170000180 (2000).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"6742_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/jcm4050782","volume":"4","author":"CW Wong","year":"2015","unstructured":"Wong, C. W., Wong, T. Y. & Cheung, C. M. G. Polypoidal choroidal vasculopathy in Asians. J. Clin. Med. 4, 782\u2013821. https:\/\/doi.org\/10.3390\/jcm4050782 (2015).","journal-title":"J. Clin. Med."},{"key":"6742_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000774","volume":"36","author":"C Balaratnasingam","year":"2016","unstructured":"Balaratnasingam, C. et al. Polypoidal choroidal vasculopathy: A distinct disease or manifestation of many?. Retina 36, 1\u20138. https:\/\/doi.org\/10.1097\/IAE.0000000000000774 (2016).","journal-title":"Retina"},{"key":"6742_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung, C. M. G. et al. Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management. Ophthalmology 125, 708\u2013724. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.019 (2018).","journal-title":"Ophthalmology"},{"key":"6742_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.oret.2018.11.003","volume":"3","author":"KY Chong Teo","year":"2019","unstructured":"Chong Teo, K. Y. et al. A multicountry comparison of real-world management and outcomes of polypoidal choroidal vasculopathy: Fight retinal blindness! Cohort. Ophthalmol. Retina 3, 220\u2013229. https:\/\/doi.org\/10.1016\/j.oret.2018.11.003 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"6742_CR10","doi-asserted-by":"publisher","unstructured":"Teo, K. Y. C., Gillies, M. & Fraser-Bell, S. The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy: A subtype of neovascular age-related macular degeneration. Int. J. Mol. Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19092611","DOI":"10.3390\/ijms19092611"},{"key":"6742_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji, M. et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: A randomized controlled trial. Adv. Ther. 37, 1173\u20131187. https:\/\/doi.org\/10.1007\/s12325-020-01236-x (2020).","journal-title":"Adv. Ther."},{"key":"6742_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong, T. Y. et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: Two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am. J. Ophthalmol. 204, 80\u201389. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.027 (2019).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/OPTH.S101596","volume":"10","author":"T Hirakata","year":"2016","unstructured":"Hirakata, T. et al. One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: Rapid morphologic recovery and subsequent visual improvement. Clin. Ophthalmol. 10, 969\u2013977. https:\/\/doi.org\/10.2147\/OPTH.S101596 (2016).","journal-title":"Clin. Ophthalmol."},{"key":"6742_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","volume":"38","author":"Y Yanagi","year":"2018","unstructured":"Yanagi, Y. et al. Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. Retina 38, 1509\u20131517. https:\/\/doi.org\/10.1097\/IAE.0000000000001758 (2018).","journal-title":"Retina"},{"key":"6742_CR15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1097\/IAE.0000000000001776","volume":"38","author":"KYC Teo","year":"2018","unstructured":"Teo, K. Y. C. et al. Comparison of optical coherence tomography angiographic changes after anti-vascular endothelial growth factor therapy alone or in combination with photodynamic therapy in polypoidal choroidal vasculopathy. Retina 38, 1675\u20131687. https:\/\/doi.org\/10.1097\/IAE.0000000000001776 (2018).","journal-title":"Retina"},{"key":"6742_CR16","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","volume":"156","author":"HJ Cho","year":"2013","unstructured":"Cho, H. J. et al. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 156, 1192-1200.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.07.001 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10384-015-0387-z","volume":"59","author":"Y Nomura","year":"2015","unstructured":"Nomura, Y. & Yanagi, Y. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Jpn. J. Ophthalmol. 59, 261\u2013265. https:\/\/doi.org\/10.1007\/s10384-015-0387-z (2015).","journal-title":"Jpn. J. Ophthalmol."},{"key":"6742_CR18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","volume":"157","author":"HM Kang","year":"2014","unstructured":"Kang, H. M. et al. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am. J. Ophthalmol. 157, 1013\u20131021. https:\/\/doi.org\/10.1016\/j.ajo.2014.01.019 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","volume":"254","author":"H Kim","year":"2016","unstructured":"Kim, H. et al. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 254, 1497\u20131503. https:\/\/doi.org\/10.1007\/s00417-015-3221-x (2016).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"6742_CR20","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1167\/iovs.12-9619","volume":"53","author":"P Jirarattanasopa","year":"2012","unstructured":"Jirarattanasopa, P. et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 53, 3663\u20133672. https:\/\/doi.org\/10.1167\/iovs.12-9619 (2012).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"6742_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","volume":"3","author":"CMG Cheung","year":"2019","unstructured":"Cheung, C. M. G. et al. The evolution of fibrosis and atrophy and their relationship with visual outcomes in asian persons with neovascular age-related macular degeneration. Ophthalmol. Retina 3, 1045\u20131055. https:\/\/doi.org\/10.1016\/j.oret.2019.06.002 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"6742_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajo.2016.12.008","volume":"177","author":"EW Chan","year":"2017","unstructured":"Chan, E. W. et al. Quantitative changes in pigment epithelial detachment area and volume predict retreatment in polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 177, 195\u2013205. https:\/\/doi.org\/10.1016\/j.ajo.2016.12.008 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR23","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1097\/IAE.0b013e31821987a4","volume":"31","author":"WR Freeman","year":"2011","unstructured":"Freeman, W. R. et al. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Retina 31, 1812\u20131818. https:\/\/doi.org\/10.1097\/IAE.0b013e31821987a4 (2011).","journal-title":"Retina"},{"key":"6742_CR24","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1097\/IAE.0000000000002195","volume":"38","author":"AM Khanani","year":"2018","unstructured":"Khanani, A. M. et al. Optimal management of pigment epithelial detachments in eyes with neovascular age-related macular degeneration. Retina 38, 2103\u20132117. https:\/\/doi.org\/10.1097\/IAE.0000000000002195 (2018).","journal-title":"Retina"},{"key":"6742_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/IAE.0000000000001342","volume":"37","author":"K Balaskas","year":"2017","unstructured":"Balaskas, K. et al. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina 37, 1297\u20131304. https:\/\/doi.org\/10.1097\/IAE.0000000000001342 (2017).","journal-title":"Retina"},{"key":"6742_CR26","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"123","author":"D Sarraf","year":"2016","unstructured":"Sarraf, D. et al. Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR Study. Ophthalmology 123, 2213\u20132224. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.007 (2016).","journal-title":"Ophthalmology"},{"key":"6742_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein, S. M. et al. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology 123, 60\u201369. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.013 (2016).","journal-title":"Ophthalmology"},{"key":"6742_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12886-018-0824-0","volume":"18","author":"P Tyagi","year":"2018","unstructured":"Tyagi, P. et al. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept. BMC Ophthalmol. 18, 148. https:\/\/doi.org\/10.1186\/s12886-018-0824-0 (2018).","journal-title":"BMC Ophthalmol."},{"key":"6742_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/IAE.0000000000000409","volume":"35","author":"GK Broadhead","year":"2015","unstructured":"Broadhead, G. K. et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina 35, 975\u2013981. https:\/\/doi.org\/10.1097\/IAE.0000000000000409 (2015).","journal-title":"Retina"},{"key":"6742_CR30","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1167\/iovs.12-9435","volume":"53","author":"J Chhablani","year":"2012","unstructured":"Chhablani, J. et al. Repeatability and reproducibility of manual choroidal volume measurements using enhanced depth imaging optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 53, 2274\u20132280. https:\/\/doi.org\/10.1167\/iovs.12-9435 (2012).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"6742_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2415-13-43","volume":"13","author":"S Sonoda","year":"2013","unstructured":"Sonoda, S. et al. Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab. BMC Ophthalmol. 13, 43. https:\/\/doi.org\/10.1186\/1471-2415-13-43 (2013).","journal-title":"BMC Ophthalmol."},{"key":"6742_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/IAE.0000000000001312","volume":"37","author":"X Wei","year":"2017","unstructured":"Wei, X. et al. Choroidal Vascularity Index: A novel optical coherence tomography based parameter in patients with exudative age-related macular degeneration. Retina 37, 1120\u20131125. https:\/\/doi.org\/10.1097\/IAE.0000000000001312 (2017).","journal-title":"Retina"},{"key":"6742_CR33","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.1038\/s41598-017-08276-4","volume":"7","author":"DSW Ting","year":"2017","unstructured":"Ting, D. S. W. et al. Choroidal remodeling in age-related macular degeneration and polypoidal choroidal vasculopathy: A 12-month prospective study. Sci. Rep. 7, 7868. https:\/\/doi.org\/10.1038\/s41598-017-08276-4 (2017).","journal-title":"Sci. Rep."},{"key":"6742_CR34","doi-asserted-by":"publisher","unstructured":"Teo, K. Y. C., Jordan-Yu, J. M. & Tan, A. C. S. et al. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318354","DOI":"10.1136\/bjophthalmol-2020-318354"},{"key":"6742_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","volume":"99","author":"CS Tan","year":"2015","unstructured":"Tan, C. S. et al. EVEREST study report 2: Imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 99, 624\u2013628. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305674 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"6742_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan, T. D. L. et al. Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration. Am. J. Ophthalmol. 224, 267\u2013281. https:\/\/doi.org\/10.1016\/j.ajo.2020.12.012 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ajo.2006.05.051","volume":"142","author":"M Sasahara","year":"2006","unstructured":"Sasahara, M. et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am. J. Ophthalmol. 142, 601\u2013607. https:\/\/doi.org\/10.1016\/j.ajo.2006.05.051 (2006).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","volume":"118","author":"SE Chung","year":"2011","unstructured":"Chung, S. E. et al. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118, 840\u2013845. https:\/\/doi.org\/10.1016\/j.ophtha.2010.09.012 (2011).","journal-title":"Ophthalmology"},{"key":"6742_CR39","doi-asserted-by":"publisher","unstructured":"Agrawal, R., Gupta, P. & Tan, K. A. et al. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. Sci. Rep. 2016. https:\/\/doi.org\/10.1038\/srep21090","DOI":"10.1038\/srep21090"},{"key":"6742_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ajo.2016.03.039","volume":"166","author":"HJ Cho","year":"2016","unstructured":"Cho, H. J. et al. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am. J. Ophthalmol. 166, 112\u2013119. https:\/\/doi.org\/10.1016\/j.ajo.2016.03.039 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"6742_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/OPTH.S56539","volume":"8","author":"M Yamashita","year":"2014","unstructured":"Yamashita, M. et al. Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin. Ophthalmol. 8, 343\u2013346. https:\/\/doi.org\/10.2147\/OPTH.S56539 (2014).","journal-title":"Clin. Ophthalmol."},{"key":"6742_CR42","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1167\/iovs.14-14610","volume":"55","author":"M Hata","year":"2014","unstructured":"Hata, M. et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Investig. Ophthalmol. Vis. Sci. 55, 7874\u20137880. https:\/\/doi.org\/10.1167\/iovs.14-14610 (2014).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"6742_CR43","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00417-011-1620-1","volume":"249","author":"H Koizumi","year":"2011","unstructured":"Koizumi, H. et al. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 249, 1123\u20131128. https:\/\/doi.org\/10.1007\/s00417-011-1620-1 (2011).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"6742_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ajo.2012.07.018","volume":"155","author":"H Koizumi","year":"2013","unstructured":"Koizumi, H. et al. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am. J. Ophthalmol. 155, 305-313.e1. https:\/\/doi.org\/10.1016\/j.ajo.2012.07.018 (2013).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06742-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:13:59Z","timestamp":1669331639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06742-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6742"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06742-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"13 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2993"}}